Citadel Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $30.4M | Sell |
68,100
-46,400
| -41% | -$21.6M | ﹤0.01% | 1853 |
|
|
2025
Q4 | $51.9M | Sell |
114,500
-21,500
| -16% | -$9.27M | 0.01% | 1378 |
|
|
2025
Q3 | $53.3M | Buy |
136,000
+10,900
| +9% | +$4.56M | 0.01% | 1318 |
|
|
2025
Q2 | $55.7M | Buy |
125,100
+20,700
| +20% | +$9.54M | 0.01% | 1161 |
|
|
2025
Q1 | $50.6M | Sell |
104,400
-67,400
| -39% | -$31.4M | 0.01% | 1136 |
|
|
2024
Q4 | $69.2M | Buy |
171,800
+77,600
| +82% | +$36M | 0.01% | 998 |
|
|
2024
Q3 | $43.8M | Sell |
94,200
-18,000
| -16% | -$8.65M | 0.01% | 1346 |
|
|
2024
Q2 | $52.6M | Sell |
112,200
-34,000
| -23% | -$14.8M | 0.01% | 1114 |
|
|
2024
Q1 | $61.1M | Buy |
146,200
+10,300
| +8% | +$4.35M | 0.01% | 1049 |
|
|
2023
Q4 | $55.3M | Sell |
135,900
-1,300
| -0.9% | -$480K | 0.01% | 1100 |
|
|
2023
Q3 | $47.7M | Buy |
137,200
+38,800
| +39% | +$13.6M | 0.01% | 1108 |
|
|
2023
Q2 | $34.6M | Sell |
98,400
-55,900
| -36% | -$18.8M | 0.01% | 1354 |
|
|
2023
Q1 | $48.6M | Sell |
154,300
-35,000
| -18% | -$10.5M | 0.01% | 1094 |
|
|
2022
Q4 | $54.7M | Sell |
189,300
-35,500
| -16% | -$10.8M | 0.01% | 1056 |
|
|
2022
Q3 | $65.1M | Sell |
224,800
-65,000
| -22% | -$18.7M | 0.01% | 854 |
|
|
2022
Q2 | $81.7M | Sell |
289,800
-175,200
| -38% | -$46.9M | 0.02% | 683 |
|
|
2022
Q1 | $121M | Buy |
465,000
+214,300
| +85% | +$50.9M | 0.03% | 570 |
|
|
2021
Q4 | $55.1M | Sell |
250,700
-61,300
| -20% | -$11.9M | 0.01% | 1097 |
|
|
2021
Q3 | $56.6M | Sell |
312,000
-353,300
| -53% | -$69M | 0.01% | 1030 |
|
|
2021
Q2 | $134M | Buy |
665,300
+362,900
| +120% | +$75.9M | 0.03% | 519 |
|
|
2021
Q1 | $65M | Buy |
302,400
+124,700
| +70% | +$27.4M | 0.02% | 836 |
|
|
2020
Q4 | $42M | Buy |
177,700
+1,200
| +0.7% | +$275K | 0.01% | 1091 |
|
|
2020
Q3 | $48M | Sell |
176,500
-31,500
| -15% | -$8.69M | 0.01% | 890 |
|
|
2020
Q2 | $60.4M | Buy |
208,000
+91,300
| +78% | +$24.8M | 0.02% | 685 |
|
|
2020
Q1 | $27.8M | Sell |
116,700
-71,600
| -38% | -$16.4M | 0.01% | 981 |
|
|
2019
Q4 | $41.2M | Buy |
188,300
+96,400
| +105% | +$19.5M | 0.02% | 892 |
|
|
2019
Q3 | $15.6M | Sell |
91,900
-400
| -0.4% | -$70.8K | 0.01% | 1719 |
|
|
2019
Q2 | $16.9M | Buy |
92,300
+32,100
| +53% | +$5.61M | 0.01% | 1592 |
|
|
2019
Q1 | $11.1M | Sell |
60,200
-149,400
| -71% | -$27.6M | 0.01% | 1943 |
|
|
2018
Q4 | $34.7M | Buy |
209,600
+121,200
| +137% | +$21M | 0.02% | 826 |
|
|
2018
Q3 | $17M | Sell |
88,400
-15,600
| -15% | -$2.78M | 0.01% | 1545 |
|
|
2018
Q2 | $17.7M | Buy |
104,000
+55,200
| +113% | +$8.56M | 0.01% | 1404 |
|
|
2018
Q1 | $7.95M | Sell |
48,800
-51,400
| -51% | -$8.4M | ﹤0.01% | 1948 |
|
|
2017
Q4 | $15M | Sell |
100,200
-21,300
| -18% | -$3.15M | 0.01% | 1369 |
|
|
2017
Q3 | $18.5M | Buy |
121,500
+77,900
| +179% | +$11.7M | 0.01% | 1112 |
|
|
2017
Q2 | $5.62M | Sell |
43,600
-500
| -1% | -$60.2K | ﹤0.01% | 2003 |
|
|
2017
Q1 | $4.82M | Buy |
44,100
+6,500
| +17% | +$572K | ﹤0.01% | 2080 |
|
|
2016
Q4 | $2.77M | Sell |
37,600
-8,300
| -18% | -$675K | ﹤0.01% | 2585 |
|
|
2016
Q3 | $4M | Buy |
45,900
+17,200
| +60% | +$1.63M | ﹤0.01% | 2202 |
|
|
2016
Q2 | $2.47M | Sell |
28,700
-9,300
| -24% | -$804K | ﹤0.01% | 2518 |
|
|
2016
Q1 | $3.02M | Buy |
38,000
+11,200
| +42% | +$1.01M | ﹤0.01% | 2235 |
|
|
2015
Q4 | $3.37M | Sell |
26,800
-20,300
| -43% | -$2.45M | ﹤0.01% | 2194 |
|
|
2015
Q3 | $4.91M | Sell |
47,100
-102,400
| -68% | -$13.2M | ﹤0.01% | 1966 |
|
|
2015
Q2 | $18.5M | Buy |
149,500
+93,300
| +166% | +$11.8M | 0.02% | 1050 |
|
|
2015
Q1 | $6.63M | Sell |
56,200
-37,000
| -40% | -$4.43M | 0.01% | 1754 |
|
|
2014
Q4 | $11.1M | Sell |
93,200
-7,700
| -8% | -$867K | 0.01% | 1332 |
|
|
2014
Q3 | $11.3M | Sell |
100,900
-88,100
| -47% | -$8.39M | 0.01% | 1278 |
|
|
2014
Q2 | $17.9M | Buy |
189,000
+31,800
| +20% | +$2.23M | 0.02% | 878 |
|
|
2014
Q1 | $11.1M | Sell |
157,200
-22,000
| -12% | -$1.74M | 0.01% | 1195 |
|
|
2013
Q4 | $13.3M | Buy |
179,200
+94,600
| +112% | +$6.59M | 0.02% | 1037 |
|
|
2013
Q3 | $6.41M | Sell |
84,600
-6,000
| -7% | -$477K | 0.01% | 1396 |
|
|
2013
Q2 | $7.24M | Buy |
+90,600
| New | +$6.67M | 0.01% | 1272 |
|
Other funds holding VRTX
VCM
VPM
Citadel Advisors's VRTX Position: Q1 2026 in Review
Citadel Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 21% in Q1 2026, selling an estimated $40.9M and leaving 339,298 shares worth $152M. The position accounts for 0.02% of the portfolio, ranked #587.
Citadel Advisors first reported a position in VRTX in Q3 2013 and has held it in 49 quarters since. The position peaked at $369M in Q1 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Citadel Advisors held 339,298 shares of Vertex Pharmaceuticals worth $152M as of Q1 2026.
- Citadel Advisors sold 87,762 Vertex Pharmaceuticals shares in Q1 2026, an estimated $40.9M.
- Vertex Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #587 holding.
- Citadel Advisors first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 49 quarters since.
- Citadel Advisors's Vertex Pharmaceuticals position peaked at $369M in Q1 2021.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.